Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

August 4, 2017: By Jon Swedien
Mynosys Zepto disposable handpiece

Mynosys’ Zepto disposable handpiece

Mynosys has received a $1 million government grant to commercialize its Zepto capsulotomy system, the Fremont, California, company announced Aug. 1.

The National Eye Institute (NEI) of the National Institutes of Health (NIH) awarded Mynosys an SB1 Commercialization Readiness Program award, which is intended to support the transition of previously NIH-funded projects to the commercialization stage. Mynosys has received $5.3 million in total from the NIH’s Small Business Innovation Research program.

The Zepto, which received US 501(k) clearance in June, is designed to allow cataract surgeons to create automated, circular, exactly sized capsulotomies tailored to the individual patient.

The system is the first non-laser automated cataract capsulotomy device to gain US approval, but several others are expected to follow. The device received CE marking in December 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023